HN

Dr Hoenle AGFRA Dr Stock Report

Last reporting period 30 Jun, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

0.081

Micro

Exchange

XFRA - Deutsche Boerse AG

HNL.F Stock Analysis

HN

Uncovered

Dr Hoenle AG is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

2/100

Low score

Market cap $B

0.081

Dividend yield

0.64 %

Shares outstanding

6.062 B

Dr. Hönle AG engages in the development, manufacture, and sale of light-emitting diode ultraviolet (UV) products. The company is headquartered in Gilching, Bayern and currently employs 636 full-time employees. The company went IPO on 2008-02-25. The firm develops, manufactures and supplies ultraviolet (UV) equipment. The firm operates three business segments: Equipment and Systems, Adhesives, and Glass and Lamps. The Equipment and Systems segment encompasses the development, production and sale of UV equipment and systems used for drying inks and coatings, for curing adhesives and plastics, disinfecting surfaces and for sunlight simulation. The Adhesives segment comprises the development, production and sale of UV industrial adhesives for the use in the automotive, electronics, medical technology and optics industries, among others. The Glass and Lamps segment includes the development, production and sale of tubing and semi-finished goods made from quartz glass as well as the manufacture of UV medium-pressure and low-pressure lamps. The firm is globally active, with over 69 locations in 27 countries.

View Section: Eyestock Rating